The effects of picumast on human eosinophil and neutrophil activation.
Moqbel
R
R
Department of Allergy and Clinical Immunology, National Heart and Lung Institute, London, U.K.
Hartnell
A
A
Kay
A B
AB
D000818:Animals; D002448:Cell Adhesion / Q000187:drug effects; D003179:Complement C3b / Q000276:immunology; D003374:Coumarins / Q000494:pharmacology*; D016207:Cytokines / Q000494:pharmacology; D004804:Eosinophils / Q000187:drug effects* / Q000276:immunology / Q000502:physiology; D005434:Flow Cytometry; D006634:Histamine H1 Antagonists / Q000494:pharmacology*; D006801:Humans; D007070:Immunoglobulin A / Q000276:immunology; D016177:Macrophage-1 Antigen / Q000378:metabolism; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology; D009504:Neutrophils / Q000187:drug effects* / Q000276:immunology / Q000502:physiology; D010972:Platelet Activating Factor / Q000494:pharmacology; D012397:Rosette Formation; D012547:Schistosoma / Q000378:metabolism; D015854:Up-Regulation / Q000187:drug effects
D003374:Coumarins; D016207:Cytokines; D006634:Histamine H1 Antagonists; D007070:Immunoglobulin A; D016177:Macrophage-1 Antigen; D010972:Platelet Activating Factor; C013373:picumast; D009240:N-Formylmethionine Leucyl-Phenylalanine; D003179:Complement C3b